Please assess the completion status of the following clinical trial:

Trial Title: Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Cohort A and B:~* Written informed consent must be obtained before any assessment is performed~* Male and female patients between the ages of 18 to 65 (inclusive) at screening~* C3G patients wit proteinuria~* Able to communicate well with the investigator, to understand and comply with the requirements of the study~* At screening and baseline visits, patients must weigh at least 35 kg~* Supine vital signs should be within the following ranges :~oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm~.~Inclusion Criteria for Cohort A:~* Estimated GFR (using the CKD-EPI formula) or measured GFR ≥30 mL/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)~* UPCR ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion)~* Prior to entry, all patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB for at least 30 days.~Inclusion Criteria for Cohort B:~* No histological/laboratory/clinical signs of allorejection~* If applicable, induction treatment after allotransplantation needs to be completed \>30 days before inclusion.~* Transplantation of a kidney allograft \>90 days before inclusion~* Patients need to be on a stable dose of immunosuppressive regimen prior to inclusion. Any approved treatments are allowed for this purpose.~Exclusion Criteria for Cohort A and B:~* Use of other investigational drugs at the time of enrollment, or within 5 half-lives of randomization, or within 30 days, whichever is longer; or longer if required by local regulations~* A history of clinically significant ECG abnormalities,~* Known family history or known presence of long QT syndrome or Torsades de Pointes~* Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.~* Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug.~* History of immunodeficiency diseases, or a positive HIV test result.~* Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).~* Patients who cannot receive vaccinations against N. meningitidis, S. pneumoniae, or H. influenzae

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A - no kidney transplant (Type: EXPERIMENTAL): C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
- Cohort B - kidney transplant (Type: EXPERIMENTAL): C3G patients who have received a kidney transplant and have C3G recurrence.

Based on this trial design, predict the completion outcome and termination type (if applicable).